AnaptysBio
ANAB
122 hedge funds and large institutions have $628M invested in AnaptysBio in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 26 closing their positions.
4.44% more ownership
Funds ownership: 102.18% → 106.62% (+4.4%)
5% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 39
5% more capital invested
Capital invested by funds: $601M → $628M (+$27.7M)
3% less call options, than puts
Call options by funds: $7.66M | Put options by funds: $7.93M
10% less funds holding
Funds holding: 136 → 122 (-14)
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$99.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$30M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.8M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$10.8M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$26.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$25.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$19.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.16M |
ANAB Hedge Fund Activity: Q1 2021 in Review
122 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2021, worth a combined $628M — up 4.6% from $601M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ANAB and 13 opened new positions — a net loss of 13 holders — while 39 trimmed existing stakes and 41 added.
The largest buyer was EcoR1 Capital, adding an estimated $99.1M. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $26.1M sold.
- 122 institutional investors held AnaptysBio (ANAB) as of Q1 2021, down from 136 in Q4 2020.
- Funds reported $628M of AnaptysBio stock for Q1 2021, up 4.6% quarter-over-quarter.
- 13 funds opened new AnaptysBio positions in Q1 2021 and 26 closed out, a net change of -13 holders.
- The largest AnaptysBio buyer in Q1 2021 was EcoR1 Capital, an estimated $99.1M added.
- The largest AnaptysBio seller in Q1 2021 was Aquilo Capital Management, an estimated $26.1M sold.
Based on aggregated 13F filings for Q1 2021.